Evidence map›Paper›PMID 39440690›Full record

ArticleCancer medicine2024

Healthcare providers' expected barriers and facilitators to the implementation of person-centered long-term follow-up care for childhood cancer survivors: A PanCareFollowUp study.

Dionne Breij, Lars Hjorth, Eline Bouwman, Iris Walraven, Tomas Kepak, Katerina Kepakova, Riccardo Haupt, Monica Muraca, Irene Göttgens, Iridi Stollman and 16 more

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Dionne BreijDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID https://orcid.org/0009-0003-4066-6675
Lars HjorthPediatrics, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Eline BouwmanDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-9149-9745
Iris WalravenDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.
Tomas KepakInternational Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Brno, The Czech Republic.ORCID https://orcid.org/0000-0002-1449-5273
Katerina KepakovaInternational Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Brno, The Czech Republic.
Riccardo HauptEpidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Monica MuracaEpidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Irene GöttgensDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.
Iridi StollmanDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.
Jeanette Falck WintherChildhood Cancer Research Group, Danish Cancer Society Research Centre, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-3440-5108
Anita KienesbergerChildhood Cancer International Europe, Vienna, Austria.
Hannah GsellChildhood Cancer International Europe, Vienna, Austria.
Gisela MichelFaculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Nicole BlijlevensDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.
Saskia M F PluijmPrincess Máxima Centre for Pediatric Oncology, Utrecht, The Netherlands.
Katharina RoserFaculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Roderick SkinnerFaculty of Medical Sciences, Newcastle University, Royal Victoria Infirmary (Sir James Spence Institute), Newcastle, UK.ORCID https://orcid.org/0000-0002-1162-675X
Marleen RenardDepartments of Pediatric Hematology and Oncology, and Oncology, University Hospitals Leuven, Leuven, Belgium.
Anne UyttebroeckDepartments of Pediatric Hematology and Oncology, and Oncology, University Hospitals Leuven, Leuven, Belgium.
Cecilia FollinPediatrics, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Helena J H van der PalPrincess Máxima Centre for Pediatric Oncology, Utrecht, The Netherlands.
Leontien C M KremerPrincess Máxima Centre for Pediatric Oncology, Utrecht, The Netherlands.
Jaqueline LoonenDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.
Rosella HermensDepartments of Hematology and IQ Health, Radboud University Medical Centre, Nijmegen, The Netherlands.
PanCareFollowUp Consortium

Funding

European Union's Horizon 2020 Research and Innovation Program 824982
6 · The paper itself

Abstract

backgroundChildhood cancer survivors face high risks of adverse late health effects. Long-term follow-up care for childhood cancer survivors is crucial to improve their health and quality of life. However, implementation remains a challenge. To support implementation of high-quality long-term follow-up care, we explored expected barriers and facilitators for establishing this follow-up care among healthcare providers from four European clinics.

methodsA qualitative study was conducted using four focus groups comprising 30 healthcare providers in total. The semi-structured interview guide was developed based on the Grol and Wensing framework. Data was analyzed following a thematic analysis, combining both inductive and deductive approaches to identify barriers and facilitators across the six levels of Grol and Wensing: innovation, professional, patient, social, organizational and economic and political.

resultsMost barriers were identified on the organizational level, including insufficient staff, time, capacity and psychosocial support. Other main barriers included limited knowledge of late effects among healthcare providers outside the long-term follow-up care team, inability of some survivors to complete the survivor questionnaire and financial resources. Main facilitators included motivated healthcare providers and survivors, a skilled hospital team, collaborations with important stakeholders like general practitioners, and psychosocial care facilities, utilization of the international collaboration and reporting long-term follow-up care results to convince hospital managers.

conclusionThis study identified several factors for successful implementation of long-term follow-up care for childhood cancer survivors. Our findings showed that specific attention should be given to knowledge, capacity, and financial issues, along with addressing psychosocial issues of survivors.

Indexed as

Cancer SurvivorsHealth PersonnelQualitative ResearchAdultAftercareAttitude of Health PersonnelChildFemaleFocus GroupsFollow-Up StudiesHumansLong-Term CareMaleNeoplasmsPatient-Centered CareQuality of Lifebarriers and facilitatorscancer survivorshipchildhood cancerfollow‐up carehealthcare providersimplementation sciencelate effects

Identifiers

PMID39440690
PMCPMC11497108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.